Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
Meritxell Bellet, Faten Ahmad, Rafael Villanueva-Vázquez, et al.
Therapeutic Advances in Medical Oncology (2019) Vol. 11
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Joerg Herrmann
Nature Reviews Cardiology (2020) Vol. 17, Iss. 8, pp. 474-502
Open Access | Times Cited: 524
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
Antonio Marra, Giuseppe Curigliano
npj Breast Cancer (2019) Vol. 5, Iss. 1
Open Access | Times Cited: 105
CDK inhibitors from past to present: A new wave of cancer therapy
Muhammad Jameel, Kinjal Bhadresha, Hang Fai Kwok
Seminars in Cancer Biology (2022) Vol. 88, pp. 106-122
Open Access | Times Cited: 57
Enhanced effect of autologous EVs delivering paclitaxel in pancreatic cancer
Hasan Al Faruque, Eun‐Sook Choi, Jung‐Hee Kim, et al.
Journal of Controlled Release (2022) Vol. 347, pp. 330-346
Closed Access | Times Cited: 51
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
Rossana Roncato, Jacopo Angelini, Arianna Pani, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 17, pp. 6350-6350
Open Access | Times Cited: 58
Abemaciclib pharmacology and interactions in the treatment of HR+/HER2− breast cancer: a critical review
Federica Martorana, Maria Vita Sanò, Maria Rosaria Valerio, et al.
Therapeutic Advances in Drug Safety (2024) Vol. 15
Open Access | Times Cited: 6
Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists
Angel Ayumi Tome Uchiyama, Pedro Alexandre Ismael Amaral Silva, Moises S Martins Lopes, et al.
Current Oncology (2021) Vol. 28, Iss. 1, pp. 783-799
Open Access | Times Cited: 40
Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis
Francisco Cézar Aquino de Moraes, Caroline R. M. Pereira, Vitor Kendi Tsuchiya Sano, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 6
A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer
Pin Zhang, Binghe Xu, Lin Gui, et al.
Biomarker Research (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 28
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer
Rossana Roncato, Lorenzo Gerratana, Lorenza Palmero, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 21
Opioid metabolism and drug-drug interaction in cancer
Matti Aapro, Stefano Fogli, Bart Morlion, et al.
The Oncologist (2024) Vol. 29, Iss. 11, pp. 931-942
Open Access | Times Cited: 4
Arbidol treatment with reduced mortality of adult patients with COVID-19 in Wuhan, China: a retrospective cohort study
Qibin Liu, Xuemin Fang, Lü Tian, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Closed Access | Times Cited: 31
New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies
Oreste Lanza, Armando Ferrera, Simone Reale, et al.
Medical Sciences (2022) Vol. 10, Iss. 2, pp. 27-27
Open Access | Times Cited: 19
A single-centre retrospective evaluation of potential drug-drug interactions in breast cancer patients undergoing CDK 4/6 inhibitors chemotherapy
Prajakta Patil, Mrunal Desai, Gayathri Baburaj, et al.
Journal of Oncology Pharmacy Practice (2025)
Closed Access
Drug-Drug interactions and special considerations in breast cancer patients treated with CDK4/6 inhibitors: A comprehensive review
Taha Koray Şahin, Gözde Kavgacı, Deniz Can Güven, et al.
Cancer Treatment Reviews (2025), pp. 102956-102956
Closed Access
The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer
Dilek Çağlayan, Mehmet Koçak, Çağlayan Geredeli, et al.
European Journal of Clinical Pharmacology (2022) Vol. 79, Iss. 2, pp. 243-248
Open Access | Times Cited: 16
Predicting drug–drug interactions in breast cancer patients treated with CDK4/6 inhibitors and forward planning
Abha Kulkarni, Jasmeet Singh
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 4, pp. 225-233
Closed Access | Times Cited: 3
The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia
Milo Gatti, Emanuel Raschi, Elisabetta Poluzzi, et al.
Current Heart Failure Reports (2020) Vol. 17, Iss. 6, pp. 365-383
Open Access | Times Cited: 20
Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
Lin Zhu, Qin Yang, Rong Hu, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 12
Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
Hatice Odabaş, Akif Doğan, Melike Özçelik, et al.
Medicina (2023) Vol. 59, Iss. 3, pp. 557-557
Open Access | Times Cited: 7
Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report
Vardan Nersesjan, Klaus Hansen, Thomas Krag, et al.
BMC Neurology (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 19
Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer
M García-Trevijano Cabetas, Pedro L. Martínez, I. Jiménez Nácher, et al.
International Journal of Clinical Pharmacy (2020) Vol. 43, Iss. 4, pp. 893-899
Closed Access | Times Cited: 17
Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer
Hope S. Rugo, Anja Haltner, Lin Zhan, et al.
Journal of Comparative Effectiveness Research (2021) Vol. 10, Iss. 6, pp. 457-467
Open Access | Times Cited: 16
Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects
Fanny Leenhardt, Frédéric Fiteni, Ludovic Gauthier, et al.
Pharmaceutics (2022) Vol. 14, Iss. 4, pp. 841-841
Open Access | Times Cited: 10
Screening for clinically relevant drug-drug interactions between direct oral anticoagulants and antineoplastic agents: a pharmacovigilance approach
Bang Truong, Lori B. Hornsby, Brent I. Fox, et al.
Journal of Thrombosis and Thrombolysis (2023) Vol. 56, Iss. 4, pp. 555-567
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top